- •CONTENTS
- •Contributors
- •Preface
- •I Components of Angiogenic Cascades
- •1. Introduction and Historical Perspective
- •2. The Semaphorins
- •3. The Plexin Receptor Family
- •4. The Neuropilins
- •5. Vascular Endothelial Growth Factors and Their Receptors
- •6. Signal Transduction by Neuropilins
- •7. The Role of the Neuropilins in the Regulation of Vasculogenesis and Angiogenesis
- •8. Modulation of Angiogenesis by Semaphorins that Bind Directly to Plexins
- •Acknowledgments
- •References
- •1. Introduction
- •1.1. Eph receptor domain structure
- •1.2. The ephrin domain structure
- •2. Effects on Vascular Cell Behavior and Signaling Pathways
- •2.1. Ephrin-A1 and EphA2
- •2.2. Ephrin-A1 and EphA4
- •2.3. Ephrin-B and EphB
- •2.3.1. EphB forward signaling
- •2.3.2. Ephrin-B reverse signaling
- •2.4. Crosstalk with other angiogenic pathways
- •3. Endothelial Cell Fate
- •4. Angiogenic Remodeling of Embryonic Blood Vessels
- •4.1. Ephrin-A1 and EphA receptors
- •4.2. EphB4 and Ephrin-B2
- •4.3. Other EphB receptors and Ephrin-Bs
- •5. Lymphatic Vessels
- •6. Adult Vasculature
- •6.1. Quiescent vasculature
- •6.2. Physiological angiogenesis
- •6.3. Inflammation and wound healing
- •6.4. Tumor angiogenesis
- •6.4.1. Ephrin-A1 and EphA2
- •6.4.2. Ephrin-B2 and EphB4
- •8. Perspectives
- •Acknowledgments
- •References
- •1. Introduction
- •2. Molecular Mechanisms
- •3. Role in Vascular Development
- •4. FGFs in Tumor Angiogenesis
- •5. Role of FGFs in Developmental and Tumor Lymphangiogenesis
- •7. Conclusion
- •Acknowledgments
- •References
- •1. The NPY System
- •2. NPY as a Growth Factor for Vascular Cells
- •3. DPPIV: A Molecular Switch of the NPY Angiogenic System
- •4. Downstream Mediators of NPY Actions
- •5. NPY in Revascularization of Ischemic Tissues
- •6. NPY in Wound Healing
- •7. NPY in Adipose Tissue Growth and Obesity
- •8. NPY in Retinopathy
- •10. NPY in Tumor Angiogenesis
- •11. NPY-Mediated Angiogenesis and Neurogenesis
- •References
- •1. Introduction
- •2. Historical Perspective
- •3.1. The HSPG core proteins
- •3.2. The structure of the HS chain
- •3.3. The biosynthesis of HS
- •3.4. The post-synthetic processing of HSPGs
- •4. Evolution of HSPGs
- •5. HSPGs in Development
- •6. HSPG Modulation of Ligand-Receptor Interactions
- •6.2. HSPG co-receptors confer unique regulatory properties
- •6.2.1. Co-receptors engender stoichiometric control of signaling
- •6.2.2. The effects of glycanation
- •6.2.3. HS sequence motifs regulate signaling
- •7. HSPGs Enable Global Control of EC Phenotype
- •8. Future Therapeutic Directions
- •9. Conclusions
- •References
- •II Angiogenic Regulators
- •1. Introduction: Blood Vessels and Nerves Use Similar Guidance Cues
- •2. Semaphorin Signaling
- •2.1. Neuropilins
- •2.2. Plexins
- •3. Ephrins and Eph Signaling
- •3.1. Forward signaling
- •3.2. Reverse signaling
- •4. Netrin and Slit Signaling
- •5. Open Questions
- •References
- •1. Oxygen Homeostasis: Phylogeny, Ontogeny, Physiology, and Pathobiology
- •5. Control of Angiogenesis and Arteriogenesis by HIF-1
- •6. Control of Tumor Angiogenesis by HIF-1
- •References
- •1. Introduction
- •2. Reactive Oxygen Species (ROS) in the Vasculature
- •3. ROS and Angiogenesis
- •4. NAD(P)H Oxidase: A Major Source of ROS in the Vasculature
- •5. Role of NAD(P)H Oxidase in Angiogenesis
- •6. ROS as Signaling Molecules in Angiogenesis
- •8. Conclusion
- •References
- •1. Introduction
- •2. Assessing Coronary Angiogenesis and Arteriogenesis
- •3. Pressure Overload-Induced Hypertrophy
- •4. Volume Overload-Induced Cardiac Hypertrophy
- •5. Thyroxine-Induced Hypertrophy
- •6. Hypoxia-Induced Hypertrophy
- •7. Exercise-Induced Hypertrophy
- •8. Myocardial Infarction-Induced Hypertrophy
- •9. Modulators of Angiogenesis During Hypertrophy
- •10. Stimuli of Angiogenesis During Hypertrophy
- •11. Summary
- •References
- •1. Introduction
- •2. Coronary Resistance
- •3. Regulation of Coronary Microvascular Tone
- •3.1. Intrinsic and extrinsic vasomotor control
- •3.2. Role of the endothelium
- •3.3. Role of metabolism and autoregulation
- •3.4. Flow-induced dilation
- •3.5. Neurohumoral influence on microcirculation
- •3.6. Intrinsic myogenic tone
- •3.7. Impact of extravascular and humoral factors on the coronary microcirculation
- •3.8. Role of venules in coronary resistance
- •4. Endothelial Factors in Vascular Growth and Response to Injury
- •5. Impact of Disease States on Coronary Circulation
- •6. The Coronary Microcirculation in Hypertophic States
- •7. Summary
- •References
- •III Clinical Applications
- •1. Kinase Inhibition and Tumor Angiogenesis
- •2. Major Angiogenesis Factors and Receptors
- •2.1. VEGF signaling
- •3. Further Angiogenesis-Related Signaling
- •4. Need for Selectivity of Anti-Angiogenic Kinase Inhibitors
- •5. Kinase Inhibitors in Clinical Development
- •5.1. BAY 43-9006 (Sorafenib)
- •5.2. PTK/ZK (Vatalanib)
- •5.3. SU11248 (Sunitinib)
- •5.9. BIBF 1120
- •5.10. Chir-258
- •5.12. SU5416 (Semaxinib)
- •6. Challenges and Future Directions
- •Acknowledgments
- •References
- •1. Introduction
- •2. Concepts and Rationales
- •3. Strategy
- •4. Clinical Trials
- •4.1. Growth factor-based, angiogenic approach
- •4.2. Cell therapy-based, vasculogenic and paracrine approach
- •5. Issues Regarding Current Strategy
- •5.1. Choice of biological agent
- •5.2. Pharmacokinetics and delivery mode
- •5.3. Monitoring of neovascularization
- •5.4. Study design
- •6. Emerging Concepts of Therapeutic Angiogenesis
- •6.1. Neovascularization responsiveness
- •6.2. Genetic determination of neovascularization
- •7. Future Prospective
- •8. Summary
- •References
- •1. Hepatocyte Growth Factor in Cardiovascular System
- •2. HGF Signaling in Endothelial Cells
- •3. Angiogenic Therapy for Ischemic Peripheral Arterial Diseases
- •4. Clinical Trial in PAD
- •5. HGF Gene Therapy for Myocardial Ischemia
- •6. HGF Gene Therapy for Restenosis After Angioplasty
- •7. Next Five Years Perspective — Future Direction of HGF Therapy
- •Acknowledgments
- •References
- •1. Endothelial Nitric Oxide in Health and Disease
- •1.1. Nitric oxide synthases
- •1.2. Physiological role of endothelial NO (“EDNO”)
- •1.3. Endothelial NO-deficiency in cardiovascular diseases
- •1.4. Therapeutic restoration of endothelial NO production in cardiovascular diseases
- •2. Nitric Oxide and Angiogenesis
- •2.2. Tumor angiogenesis and NO
- •2.3. Evidence in cultured endothelial cells and in rabbit cornea
- •2.4. Role of NO in post-ischemic revascularization
- •2.6. Molecular mechanisms
- •3. NOS Gene Transfer
- •3.1. Gene delivery vectors
- •3.2. NOS-III gene transfer
- •3.3. NOS-II gene transfer
- •4.1. Impaired angiogenesis and arteriogenesis in patients with critical limb ischemia
- •4.2.1. NOS-III-KO mice
- •4.2.2. NOS-III transgenic mice
- •4.2.3. Wild-type NOS-III gene transfer in normal rats
- •4.5.1. Plasmid delivery of the NOS1177D gene
- •4.5.2. Adenoviral delivery of the NOS1179D gene
- •6. Conclusions
- •Acknowledgments
- •References
- •Index
10
Regulation of Coronary
Vascular Tone and
Microvascular Physiology
by Basel Ramlawi, Munir Boodhwani and Frank W. Sellke
1. Introduction
There are many cell types that make up the walls of blood vessels. The innermost layer is made of endothelial cells. This intimal endothelial layer is surrounded by a variable number of layers of smooth muscle cells comprising the medial layer. The adventitial layer surrounds the vascular smooth muscle layers. This last layer is responsible for providing structural integrity to the blood vessel, particularly larger arteries. While initially the endothelium was thought mainly to serve as a barrier to the diffusion of macromolecules, much has recently been learned about the pivotal role it plays in vascular function, regulation of vascular tone and control of local blood flow.1 Smooth muscle cells also control vascular tone via humoral vascoactive factors, neural mediators or local paracrine factors (Fig. 1).
The classification of microvessels based on structural characteristics is rather arbitrary and there is lack of uniformity in the definitions
281
282 B. Ramlawi et al.
Fig. 1. Regulation of vascular tone by factors released from the endothelium, activated platelets and leukocytes, neuronally released factors and circulating substances. Ang, angiotensin; 5HT, 5-hydroxytrypamine (serotonin); ET, endothelin; ADP, adenosine diphosphate; EDHF, endothelium-derived hyperpolarizing factor; PGI2, prostaglandin I2; Ach, acetylcholine; NE, norepinephrine. (Adapted from Ref. 71.)
of microvascular segments such as small arteries, arterioles, venules, and so on. The transition between these segments is gradual and there is no clear demarcation between them. In general, “microvessels” are defines as vessels < 300 µm in internal diameter. Capillaries are the smallest blood vessels defined as vessels whose walls are composed of only endothelial tubes. The microvessels through which blood flows toward capillaries are defined as “arterial microvessel” and those that drain from capillaries are defined as “venous microvessel.”2 Arterial microvessels usually have three coats, i.e. a thin tunica intima; a relatively thick tunica media, composed of one to several layers of smooth muscle cells disposed circumferentially; and a tunica adventitia, which
Regulation of Coronary Vascular Tone and Microvascular Physiology |
283 |
is made up of fibrous elements and fibroblasts. Venous microvessels collect the blood from capillaries and have thinner vascular walls compared with arterial microvessels. Venules, 50 µm in diameter do not possess smooth muscle cell layers. Smaller venules have only endothelial cells and pericytes, and these venules are the most permeable sites that play an important role in substance exchange.
The various vascular beds within the body possess many similarities and subtle differences. This chapter will particularly focus on the coronary microcirculation. The regulation of myocardial perfusion is dependent on many intrinsic and extrinsic factors that may be affected by atherosclerotic lesions. For this reason, a thorough understanding of coronary flow regulation is critical for optimal care of cardiac patients. It has been shown that vasomotor regulation of coronary vessels, in addition to the actual anatomy, plays an important role in coronary perfusion and operative decision making. Myocardial blood flow is largely also dependent on the resistance generated by the microcirculation. While early coronary vasomotor regulation studies consisted of indirect assessments using measurements of coronary flow and calculations of coronary resistance, more recent investigations yielded much information into the properties of the intact coronary circulation and modern methods of analysis for interpretation of physiological data.3−6
The coronary microcirculation possesses unique features that allow it to respond to the dynamic changes in nutrient requirements as well as interact with surrounding contractile tissue. As in other vascular beds, it is composed of arterioles, capillaries and venules. This chapter will focus on issues relating to coronary physiology and pharmacology as well as myocardial perfusion in relation to the microcirculation.
2. Coronary Resistance
An understanding of vascular resistance is important as it is these resistance vessels that cause pressure losses and are responsible for regulation of myocardial perfusion. Initially it was thought that the precapillary arterioles were responsible for vascular resistance, with little resistance involvement by the vessels larger than 25–50 µm in diameter. Subsequent work revealed that over half of total coronary resistance
284 B. Ramlawi et al.
Fig. 2. Intravascular pressures in the coronary microcirculation under basal conditions and during vasodilation with dipyridamole. The distribution of vascular resistance is not static. Rather the size of the vessels regulating vascular tone depends on the tone of the vasculature. (Adapted from Ref. 9.)
is caused by vessels larger than 100 µm and can be observed in vessels larger than 300 µm.7,8 Also, contrary to previous belief, the venous circulation under similar conditions of vasodilation, may account for up to 30% of vascular resistance. Figure 2 shows that under the vasodilatory effects of dipyridamole, larger arteries and veins assume a greater resistance role.8,9 Similarly, ischemia results in a significant redistribution of vascular resistance.9 This reveals that the distribution of vascular resistance is dynamic and is dependent on vascular tone among other factors.
The redistribution of microvascular resistance may change the myogenic tone in each microvascular segment because the luminal pressure in a certain vascular segment is determined by the systemic pressure and the relative distribution of vascular resistance. That is, when resistance is shifted upstream by dilation of small arterioles, for instance, the luminal pressure in the upstream microvessels decreases, resulting in myogenic
